DWTX
$3.22
Pre-MarketAs of Mar 17, 8:00 PM UTC
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.22
Potential Upside
5%
Whystock Fair Value$3.38
Price
UndervaluedFair ValueOvervalued
Fundamentals
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$103.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-930.96%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.90
Recent News
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron
Dogwood Therapeutics (DWTX) said Monday that an interim analysis of its Phase 2b study for Halneuron
Potential Government Shutdown in Focus as US Equity Futures Rise Pre-Bell
US equity futures were higher pre-bell Monday as traders appeared to brush off concerns over a poten